MORRISTOWN, N.J., March 18 /PRNewswire/ -- Concerns still persist within the general clinical community regarding the cardiovascular and gastrointestinal risk that is associated with the use of analgesics such as the nonsteroidal anti-inflammatory drugs (NSAIDs). In particular, the use of COX-2 selective inhibitor NSAIDs continues to raise the concern of cardio-renal complications not only in the decision making process of physicians but also in the perception of many patients who still recall the media blitz of reports surrounding the cardiovascular complications associated with the long term use of Vioxx and other "COX-2" analgesics. This is remarkable since simple analgesics such as acetaminophen (Tylenol(R)) and the NSAIDs are the single most commonly used and prescribed category of drug on a world wide basis. Hence, to address these important clinical day-to-day patient management concerns, CMEFirst, LLC, developed and convened a CME symposium on February 7, 2009, at the Omni Hotel in central Los Angeles.
(Photo: http://www.newscom.com/cgi-bin/prnh/20090318/NY85776 )
The location was chosen to ensure the availability of a large number of primary care physicians, internists, orthopedic surgeons, and pain specialists. The faculty recruited for the symposium represented a national and international group of renowned clinicians and investigators who have had extensive experience in the clinical development of analgesics and NSAID compounds from the perspective of clinical trial investigation as well as FDA advisory roles in the decision making processes that lead to the approval and regulation of the use of these drugs.
The initial speaker at the symposium, Allan Gibofsky, MD, JD, is an acclaimed Rheumatologist and is past Chairman of the FDA Arthritis Advisory Committee. In addition, Dr. Gibofsky is the former President of The
'/>"/>
| SOURCE CMEFirst Copyright©2009 PR Newswire. All rights reserved |